Botulinum Toxins - Myobloc
Customize your policy alerts
Sign up for Cigna Policy IP0509 alerts
Get alerted when Policy IP0509 changes without checking for updates manually.
Monitor payer policy activity
This policy governs benefit coverage and prior authorization for Myobloc (rimabotulinumtoxinB injection) administered under Cigna health benefit plans. Coverage is subject to the applicable benefit plan, covered diagnoses and codes, documented medical-necessity criteria, and dosing requirements.
Cervical dystonia criteria and dosing requirements were revised.
The upper-limb spasticity dosing limit was reduced.
Noncovered uses are now explicitly limited to cosmetic use, while other uses remain subject to medical-necessity criteria and available evidence.
Four CPT codes were removed from the coding information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.